ProfileGDS5678 / 1455549_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 80% 81% 80% 79% 80% 81% 82% 83% 83% 86% 84% 84% 86% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.5824480
GSM967853U87-EV human glioblastoma xenograft - Control 25.8215481
GSM967854U87-EV human glioblastoma xenograft - Control 35.6243380
GSM967855U87-EV human glioblastoma xenograft - Control 45.6470479
GSM967856U87-EV human glioblastoma xenograft - Control 55.7458580
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5970681
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.8012182
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 36.0505983
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 46.1248683
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 16.5309586
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 26.208484
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 36.2944184
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 46.5414186
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.8216281